Although the pathophysiological mechanisms in FXS are some of the most understood among the genetic synaptopathies, therapy for this disorder currently consists of symptom management and not pharmacological correction or reversal of synaptic changes due to loss of FMRP. Here, FMR1 is linked to fragile X syndrome.